Tag: Tryp Therapeutics - Psychedelic Alpha

Read more about the article Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience Conference

Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience Conference

Post published:November 29, 2022
Post category:Press Release

Read more about the article Tryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin

Tryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin

Post published:October 3, 2022
Post category:Press Release

Read more about the article Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment

Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment

Post published:June 29, 2022
Post category:Press Release

Read more about the article Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida

Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida

Post published:March 23, 2022
Post category:Press Release

TRYP THERAPEUTICS INC. ANNOUNCES BOARD CHANGES AND CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Post published:February 22, 2022
Post category:Press Release

Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder

Post published:December 23, 2021
Post category:Press Release

Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders

Post published:November 18, 2021
Post category:Press Release

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Fibromyalgia

Post published:November 2, 2021
Post category:Press Release

Tryp Therapeutics Reports Clinical Hold on Proposed Phase 2a Study in Eating Disorders

Post published:October 20, 2021
Post category:Press Release

Tryp Therapeutics Announces Collaboration with Researchers at the University of Wisconsin-Madison

Post published:October 7, 2021
Post category:Press Release

Weekly Bulletin

Your weekly recap of news and analysis from the psychedelic sector.

Research Review

A monthly review of the most important psychedelics research.

News & Interviews

The latest news from across the psychedelics space.

Psychedelics Patent Trackers

We track the latest patents and filings related to psilocybin, MDMA and DMT.

Psychedelic Legalization & Decriminalization Tracker

Mapping psychedelic drug policy reform across the United States

Psychedelics Drug Development Tracker

From drug discovery to regulatory approval, we map drug development in psychedelics.

Stocks & Companies Directory

A directory of all the major psychedelics stocks, companies and ETFs.

Sector Landscape Map

Explore the Psychedelic Sector Landscape visually using our new tool.

Stock Watchlist

A one-stop overview of psychedelics stocks financial performance.

Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience Conference

Tryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin

Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment

Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida

TRYP THERAPEUTICS INC. ANNOUNCES BOARD CHANGES AND CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder

Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Fibromyalgia

Tryp Therapeutics Reports Clinical Hold on Proposed Phase 2a Study in Eating Disorders

Tryp Therapeutics Announces Collaboration with Researchers at the University of Wisconsin-Madison

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.